The US Patent No 7,704,977, ‘Solid Oral Dosage Form Containing an Enhancer’ covers Orazol tablets, an oral form of zoledronic acid, a bisphosphonate. The expiry date on this patent is 2027.
Orazol is in development to treat bone metastases associated with prostate, breast and other cancers; the current gold standard of treatment is intravenous bisphosphonates.
Orazol has been designed to improve this treatment through the numerous benefits of oral administration combined with comparable efficacy.
Orazol uses Merrion’s proprietary GIPET technology which allows the oral dosing of drugs previously only available in intravenous form.
Merrion Pharmaceuticals said that thus, products developed with this technology have potential for improving the quality of life for patients as well as providing greater access to the medication with substantial economic improvements for hard pressed healthcare systems.
A separate patent, covering GIPET technology combined with bisphosphonates, of which zoledronic acid is a member, was issued in the US in March 2010 and a patent covering the GIPET technology, including its use with bisphosphonates, has been granted in Europe.
John Lynch, CEO of Merrion Pharmaceuticals, said: “This is the second key US patent issued for Merrion’s GIPET technology this year and is a significant development for our patent estate. This further establishes us as one of the leading companies in this space.
“The clinical validation for GIPET technology is also growing. For example Orazol demonstrated excellent results in a Phase 2b study published at last year’s meeting of the American Society of Clinical Oncology (ASCO). This US patent is another step towards achieving our overall vision.”